Sanofi obesity pill set for European safety assessment
The European Medicines Agency (EMEA) is reviewing Acomplia a month after US regulators rejected the drug on the grounds that the drug’s benefits failed to outweigh side-affects, including
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).